Protagen and Inova Diagnostics Partner to Advance New Systemic Sclerosis Biomarker

Protagen AG and Inova Diagnostics have signed a semi-exclusive license agreement for BICD2, a new autoantigen and the first proprietary biomarker discovered by Protagen using its SeroTag technology, a diagnostic platform. The newly discovered anti-BICD2 autoantibodies are found in about 30% of patients with…

Protagen’s Diagnostic Test for Scleroderma, Multilisa BICD2, Receives CE Mark from EU

Protagen AG, a biotechnology company specializing in diagnostic tests for autoimmune diseases, announced that their product Multilisa BICD2, for the diagnosis of scleroderma, gained CE marking.